These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12419032)

  • 21. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve.
    Musters AM; van Wely M; Mastenbroek S; Kaaijk EM; Repping S; van der Veen F; Mochtar MH
    Hum Reprod; 2012 Jan; 27(1):244-50. PubMed ID: 22095792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.
    Revelli A; Pettinau G; Basso G; Carosso A; Ferrero A; Dallan C; Canosa S; Gennarelli G; Guidetti D; Filippini C; Benedetto C
    Reprod Biol Endocrinol; 2015 Jul; 13():77. PubMed ID: 26209525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles.
    Mochtar MH; Van der Veen ; Ziech M; van Wely M
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005070. PubMed ID: 17443569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the combination of recombinant follicle-stimulating hormone and recombinant luteinizing hormone protocol versus human menopausal gonadotropin protocol in controlled ovarian stimulation: A systematic review and meta-analysis.
    Wang Y; Li L; Deng K; Liu J; Liu Y; Zou K; Hao G; Sun X
    J Evid Based Med; 2020 Aug; 13(3):215-226. PubMed ID: 32627395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization.
    Sills ES; Levy DP; Moomjy M; McGee M; Rosenwaks Z
    Hum Reprod; 1999 Sep; 14(9):2230-5. PubMed ID: 10469685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.
    Balasch J; Fábregues F; Creus M; Peñarrubia J; Vidal E; Carmona F; Puerto B; Vanrell JA
    J Assist Reprod Genet; 2000 Jan; 17(1):20-7. PubMed ID: 10754779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
    Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
    Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM; Kolibianakis EM; Camus M; Tournaye H; Donoso P; Papanikolaou E; Devroey P
    Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.
    Cheung AP; Pride SM; Yuen BH; Sy L
    Hum Reprod; 2002 Oct; 17(10):2540-7. PubMed ID: 12351525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study.
    Hugues JN; Soussis J; Calderon I; Balasch J; Anderson RA; Romeu A;
    Hum Reprod; 2005 Mar; 20(3):629-35. PubMed ID: 15618252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis.
    Hill MJ; Levens ED; Levy G; Ryan ME; Csokmay JM; DeCherney AH; Whitcomb BW
    Fertil Steril; 2012 May; 97(5):1108-14.e1. PubMed ID: 22365075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings: a multicenter observational analysis.
    Schwarze JE; Crosby JA; Zegers-Hochschild F
    Fertil Steril; 2016 Dec; 106(7):1714-1717.e1. PubMed ID: 27678033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone.
    Esposito MA; Barnhart KT; Coutifaris C; Patrizio P
    Fertil Steril; 2001 Mar; 75(3):519-24. PubMed ID: 11239535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.
    Daya S; Gunby J
    Cochrane Database Syst Rev; 2000; (4):CD002810. PubMed ID: 11034767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.